Results 11 to 20 of about 55,357 (300)
Botulinum toxin type A in treatment of chronic migraine, spasticity and bruxism
Journal of Education, Health and Sport, 2023 Introduction: Nowadays, botulinum toxin has found use in many disease entities such as chronic migraine, spasticity, bruxism and many others. Among serotypes A-E, type A is mainly used in treatment.
Klaudia Kuliga +9 more
doaj +1 more source
Current status and future directions of botulinum neurotoxins for targeting pain processing. [PDF]
, 2015 Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into peripheral tissues such as skin, muscles, and joints, alter nociceptive processing otherwise initiated by inflammation or nerve injury in animal models and humans.
Pellett, Sabine +2 more
core +5 more sources
Toxins, 2022 The efficacy and safety of botulinum toxin injection have made it a popular aesthetic procedure worldwide. A cross-sectional survey was performed in order to determine the pattern of type A botulinum toxin injections in cosmetic practice, for which an 18-
Nark-Kyoung Rho +2 more
doaj +1 more source
Treatment of masseteric hypertrophy with botulinum toxin : a report of two cases [PDF]
, 2010 Masseter muscle hypertrophy is a rare condition of unknown cause which is important in the differential diagnosis of head and neck masses, located in the cheek.
Bas, Burcu +3 more
core +1 more source
Clinical Relevance of Botulinum Toxin Immunogenicity [PDF]
, 2012 Botulinum toxin type A is a 150 kD protein produced by Clostridium botulinum, which exists in a complex with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the neuromuscular junction has been exploited ...
Reiner Benecke
core +1 more source
Botulinum toxin type A injections for treatment of chronic anal fissures
Амбулаторная хирургия, 2021 An anal fissure is one of the most common diseases of the anal canal with the incident rate of 20–23 cases per 1000 citizens. Most of acute anal fissures are healed spontaneously but a few of them can become chronic process.
M. V. Abritsova, N. R. Torchua
doaj +1 more source
The Effect of Botulinum Toxin Type A in Patients with Essential Blepharospasm
Acta Clinica Croatica, 2022 The aim of this study was to determine the effect of botulinum toxin type A and satisfaction in patients with essential blepharospasm. The study included 12 subjects suffering from essential blepharospasm who received therapy with botulinum toxin type ...
Klara Gaćina +3 more
doaj +1 more source
Genomic and physiological variability within Group II (non-proteolytic) Clostridium botulinum [PDF]
, 2013 BACKGROUND: Clostridium botulinum is a group of four physiologically and phylogenetically distinct bacteria that produce botulinum neurotoxin. While studies have characterised variability between strains of Group I (proteolytic) C. botulinum, the genetic
Andrew T Carter +6 more
core +1 more source
Botulinum toxin injections as a method for chemically denervating skeletal muscle to test functional hypotheses: a pilot study in Lepomis cyanellus [PDF]
, 2007 In this study, we demonstrate that botulinum toxin can be used to chemically denervate muscles to test functional hypotheses. We injected research-grade type A botulinum toxin complex into pectoral fin abductors (abductor superficialis) of green sunfish (
Gibb, Alice C., O'Neill, Matthew W.
core +1 more source
PLoS ONE, 2014 Botulinum neurotoxin (BoNT) is the most poisonous substances known and its eight toxin types (A to H) are distinguished by the inability of polyclonal antibodies that neutralize one toxin type to neutralize any of the other seven toxin types.
Nir Dover +5 more
doaj +1 more source